On Wednesday, LendingClub Corp (NYSE:LC)’s shares inclined 0.21% to $14.04.
Lending Club (LC) declared that Sandeep Bhandari, Assistant Chief Credit Officer at Capital One Bank (Credit Risk Administration) and Venture Partner (Capital One Ventures), will join Lending Club as Chief Credit Officer on August 24.
Bhandari will assume responsibility for credit risk administration across all products, replacing in that capacity Lending Club Chief Risk Officer Chaomei Chen, who will be retiring at the end of this year.
LendingClub Corporation operates as an online marketplace for connecting borrowers and investors in the United States. Its marketplace facilitates various types of loan products for consumers and small businesses, counting unsecured personal loans, super prime consumer loans, unsecured education and patient finance loans, and unsecured small business loans.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares gained 2.07% to $3.45.
Arena Pharmaceuticals, Inc. (ARNA) stated financial results for the second quarter ended June 30, 2015, and offered a corporate update.
Second Quarter and Recent Developments
Arena Research & Development
- Declared the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.
- Arena and Roivant Sciences Ltd. reached a Development, Marketing and Supply Agreement for nelotanserin, Arena’s internally discovered inverse agonist of the serotonin 2A receptor.
- Declared results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent cannabinoid 2 (CB2) receptor agonist in development as a potential treatment for pain.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
At the end of Wednesday’s trade, Twenty-First Century Fox Inc (NASDAQ:FOX)‘s shares dipped -0.84% to $29.48.
Twenty-First Century Fox, Inc. (FOX) stated financial results for the three months and full year ended June 30, 2015.
Full Year Company Results
The Company stated total revenues of $28.99 billion, a $2.88 billion decrease from preceding year revenues of $31.87 billion. Not taking into account the net revenues from the Direct Broadcast Satellite Television (“DBS”) businesses, Sky Italia and Sky Deutschland AG, which were sold in November 2014 to Sky plc (“Sky”), in both years, adjusted revenues raised $890 million, or 3%, over the $26.06 billion of adjusted revenues in the preceding year. This enhance was primarily driven by double-digit revenue growth at the Cable Network Programming segment.
The Company stated annual total segment operating income before depreciation and amortization (“OIBDA”) of $6.72 billion which is equal to the amount stated in the preceding year. Not taking into account the OIBDA contributions from the DBS businesses in both years, OIBDA raised $197 million, or 3%, over the $6.29 billion of adjusted OIBDA in the preceding year, due to higher contributions from the Company’s Cable Network Programming and Filmed Entertainment segments.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming, Television, Filmed Entertainment, and Direct Broadcast Satellite Television segments. The Cable Network Programming segment produces and licenses news, business news, sports, general entertainment, and movie programming for distribution primarily through cable television systems, direct broadcast satellite operators, telecommunications companies, and online video distributors in the United States, Latin America, Europe, and Asia.
Computer Sciences Corporation (NYSE:CSC), ended its Wednesday’s trading session with 4.00% gain, and closed at $66.77.
Computer Sciences Corporation ( CSC) declared a milestone in the planned spin-off of its U.S. public sector business into a separate, publicly traded company with the filing of an initial Form 10 Registration Statement (Form 10) with the U.S. Securities and Exchange Commission.
The intent to separate CSC into two companies – one to serve public sector clients in the U.S. and one to serve commercial and government clients globally – was declared on May 19. The spin-off of the public sector business will be effected through a one-for-one distribution of the new entity’s stock to CSC shareholders, and will comprise a special dividend of $10.50 per share at closing.
Computer Sciences Corporation provides information technology (IT) and professional services and solutions primarily in North America, Europe, Asia, and Australia. The company operates through Global Business Services, Global Infrastructure Services, and North American Public Sector segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
